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Objectives . This study was conducted to determine the efficacy
and safety of long-term treatment with the orally active dopamine
t i mine In patients with mild to moderate chronic
congestive heart failure and to compare the results with those of
treatment with digoxin and placebo .
l ire and dkoxin are drugs that exert hemo-
dynamic and neu Because there Is accumulating
evidence that p of disease in chronic heart failure Is related
not only to hemodynamic but also to neur dtumoral factors, both
drugs t be a to have a favorable long-term effect.
Me" . We studied 161 patients with mild to moderate
chronic been failure (80% in New York Heart Association
functional class II and 20% in class Iii), who were treated with
ibopamine (a = S3), digoxin (a = SS) or placebo (n = 53) for 6
months. round therapy consisted of furosemide (0 to
80 mg) ; all other drugs for heart failure were excluded . Clinical
assessments were made at baseline and after 1, 3 and 6 months .
pester. Of the 161 patients, 128 (80%) completed the study .
Compared with placebo, d n but not ibo ine significantly
Congestive heart failure is characterized by an impaired
quality of life and a reduced life expectancy . Initial loss of
contractile tissue leads to increased wall stress, remodeling
and reactive hypertrophy with a subsequent further decrease
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increased exercise time after 6 months (p = 0 . v intention to
treat analysis) . Ibo was only effective in patients with rela-
tively preserved left ventricular function, as it significantly increased
exercise time in this su p (for patients with a left ventricular
ejection fraction >0.30; p = 0 .019 vs . placebo)
. No patient receiving
withdrew digoxin
from the study because of progression or head
failure, coo with six patients receiving ibopamine and two
i placebo. At 6 months, plasma norepinephrine was de-
creased with digoxin and ibo a therapy (--106 and -13 pgl
,
respectively) but i with placebo administration (+62 pg(nd)
( p < 0.05 vs. placebo) . Plasma a1dosterone was unaffected, but
renin was d by both agents after 6 months (p < 0.05 vs .
placebo). T mortality ambulatory arrhythmias were not
significantly affected by the two drugs .
Conclusions , ine and digoxin both inhibit neurohumoral
activation In patients with mild to moderate chronic heart failure .
However, the clinical effects of these drugs are different and appear
to be related to the d of left ventricular dysfunction.
(J Am Cold Cardiol 1993®22 :1564-73)
in contractility (1). Although these changes are partly caused
by hemodynamic factors, neurohumoral activation also
plays an important role in this process (2) . As a conse-
quence, drugs that favorably affect both Itemodynamic and
neurohumoral changes would seem beneficial in the early
treatment of heart failure .
lbopamine is an orally active dopamine agonist with bene-
ficial hemodynamic and neurohumoral properties (3) . After
ingestion, it is hydrolyzed to epinine (N-methyldopamine),
which activates dopamine receptors and, at higher doses, beta-
and alpha-receptors (3-5) . Because ibopamine is not detectable
after oral administration, its hemodynamic effects are attrib-
uted to epinine. In the doses clinically used, this mainly results
in vasodilation and negligible positive inotropic action (6) . In
addition, ibopamine reduces plasma norepinephrine levels in
patients with advanced heart failure (7,8), which is partly due
to a direct (presumably dopamine 2-) receptor-mediated effect
0735-10971931$6 .00
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. Digoxin also exerts beneficial hemodynamic and neuro-
humoral effects (9). Although the value of digoxin in patients
with sinus rhythm and heart failure has often been questioned
(10), it has recently been suggested (11) that its long-term
beneficial influence, if any, in heart failure may be the result of
a favorable neurohumoral effect .
The purpose of the present study was to examine the
long-term effects of ibopamine and digoxin in patients with
mild to moderate chronic heart failure who were using either
no medication or low dose diuretic agents . Accordingly, the
clinical efficacy of these drugs was examined and related to
their neurohumoral effects . To detect their arrhythmogenic
potential, 24-h ambulatory Holter recordings were per-
formed .
Methods
This study was a double-blind, randomized, parallel
group comparison of ibopamine (100 mg three times daily),
digoxin (0.25 mg once daily) and placebo, conducted at 17
centers in The Netherlands, in patients with New York
Heart Association functional class 11 or III chronic conges-
tive heart failure . A single-blind placebo run-in period of 7 to
10 days was followed by a double-blind treatment period of
6 months, in which a double-dummy technique was used .
Patients were randomly assigned to each of the treatment
arms in a ratio of 1 :1 :1 . The protocol was approved by the
Ethics Committee of each participating center and was
conducted in accordance with the revised Declaration of
Helsinki. Before the study, all patients gave informed,
written consent . The study was monitored by an external
Policy Advisory Board of nonparticipating physicians .
Patients aged 18 to 75 years who were clinically stable on
fixed oral medication, if any, for & weeks before the study
were selected for the trial . Heart failure was characterized
by clinical signs and symptoms and a radionuclide left
ventricular ejection fraction :50.45 (obtained within the
previous 2 months). In addition, patients had to be able to
exercise for L-4 min and at 70 W on a bicycle ergometer . A
maximum of 80 mg/day of furosemide was allowed, as well
as short-acting nitrates . Triamterene was also permitted to
control serum potassium levels . Other drugs for heart failure
and calcium antagonists were not allowed .
Patients were excluded from participation if they had
heart failure due to hemodynamically significant valvular or
congenital heart disease, active myocarditis, thyroid disease
or hypertrophic obstructive cardiomyopathy . Further exclu-
sion criteria were exercise-limiting angina pectoris, myocar-
dial infarction or major surgery within the previous 2
months, severe hypertension (diastolic blood pressure
7105 mm Hg), atrial fibrillation or flutter with a ventricular
response 7110 beats/min at rest, pacemaker therapy, (a
history of) sustained ventricular tachyarrhythmias, renal
disease (plasma creatinine 7165 Amol/liter), chronic ob-
structive lung disease (limiting exercise tolerance), sevei -e
hepatic disease, insulin-dependent diabetes mellitus and
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psychiatric illnesses or use of monoamine oxidase inhibitors
or (anti-) dopaminergic agents, or both .
During a 7- to 10-day washout period, the clinical stability
of each patient was confirmed and routine and cardiac
studies were performed, including 24-h ambulatory electro-
cardiographic (ECG) monitoring and bicycle ergometry to
familiarize patients with the test
. The exercise protocol
started at 50 W for the I st 2 min and increased every 2 min
by 20 W. Heart rate and blood pressure were measured
before, during and after the test, and the ECG was moni-
tored continuously during exercise and recovery. Venous
blood was drawn after L-30 min of bed rest for plasma
neurohumoral variables (8) and drug concentrations . Plasma
norepinephrine, aldosterone, renin, free epinine and digoxin
concentrations were analyzed in a central core laboratory .
Plasma norepinephrine and epinine (12) and plasma renin
(13) were measured as described previously ; aldosterone and
digoxin were measured by commercially available radioim-
munoassay kits (Aldokit, Labservice Benelux, Apeldoorn,
The Netherlands, and SPAC-Digoxin, Byk-Samptec Diag-
nostica, Dietzenbach, Germany, respectively) . Reported
plasma epinine and digoxin concentrations are values mea-
sured 1 to 3 h and 1 to 10 h after ibopamine and digoxin
ingestion, respectively .
Severity of heart failure was assessed by counting the
required dose of furosemide and by using a standardized
heart failure score and a visual analog scale . In the first, the
physician rated symptoms of dyspnea and peripheral edema
on a 4-point scale (I = absent to 4 = severe) for each
variable, and with the visual analog scale complaints of
dyspnea and fatigue (0 = not at all to 10 = very much) were
scored by the patient. Ambulatory 24-h ECG recordings
were analyzed in a central core laboratory . Arrhythmias
were scored and proarrhythmia was determined using stan-
dard methods (14) .
Follow-up visits were scheduled after 1, 3 and 6 months .
Reasons for premature termination of the study were clinical
deterioration of heart failure, requiring >80 mg of furo-
semide or other drugs for heart failure, or hospital admis-
sion. In addition, unstable angina pectoris, myocardial in-
farction or a clinically significant increase in arrhythmias
was also considered a reason for dib .okitinuation of the study
medication . Side effects reported by thee patients were doc-
umented. If patients had more than one side effect, these
were recorded separately . However, if a patient reported a
particular side effect on more than one occasion, this was
scored only once .
Statistical analysis . The primary end point of the study
was duration of exercise time . Secondary end points in-
cluded prevention of deterioration and (influence on) symp-
toms of heart failure, effects on neurohumoral variables and
clinical safety-in particular, effects on 24-h ambulatory
arrhythmias . In addition to evaluation of these end points in
the study as a whole, it was prospectively determined that
the influence of ibopamine and digoxin on exercise time
would also be analyzed in various subgroups . For this, the
161 study
19 patients excluded from primary analysis (7-5-7)
4 : inability to perform adequate exercise test
4: withdrawal of CHIP medicatioNriinical instability
52 weeks prior to, randomization
3: wrong exercise protocol
2;
Insulin-dependent diabetes maliittrs
2:
exercise test limited by angina pectoris
2: (previously unknown) ventricular tachycardia an baseline
24-hour Hotter, for which the attending physician felt it
was necessary to stop the (blinded) study medication
1 : 120 mg furosemlde at entry to the study
1 : patient non-compliance
elation (93.55.3)
33 patients premature
end-of-trial
(15 .8.12)
6: died during study (1 .2 .3)
cardiac : sudden (0-2-2)
cerdiogenic shock
(1-0-0)
non-cardiac : septic shock (0.0
.1)
a: progressive heart failure (6-0-2)
6: si : nausea
(2
.2.1), dizziness (1-0-0)
5: arrhythmias: ventricular (1-0-2),
supraventricular (10.1)
3: angina pectoris (1 .0.1), myocardial infarction (0.0
.1)
2: increase blood glucose (1-1-0)
3:
	
other (1 .1 .1)
128 tie study completed (33-49 .41)
following baseline variables were used : left ventricular ejec-
tion fraction, New York Heart Association functional class,
exercise time, plasma norepinephrine, renin and aldoste-
rone, presence or absence of ventricular tachycardia and
furosemide use versus no use . These subgroup analyses
were carried out to determine whether either drug would be
more beneficial in a particular group of patients, whereby
patients were divided by using rounded off values that were
closest to the mean (normal distribution) or median (abnor-
mal distribution) .
Exercise data at 3 and 6 months were also evaluated by
intention to treat analysis to ensure that all eligible patients
were included and hence to confirm that no bias had arisen
from missing data. To accomplish this, we used a nonpara-
metric approach in which all patients who dropped out of the
study (including the ones who died) were assigned lowest
rank (that is, the values for the patient in that particular
group with the worst exercise test results were substituted
for the nonavailable data) .
It was estimated that 150 patients (50 in each of the three
ups) would have to complete the study to give a
chance of detecting a 60-s increase in exercise duration
between placebo and ibopamine at the p = 0 .05 level .
Therefore, 1
; patients were recruited, expecting a dropout
rate of approximately 15% .
The distribution of the baseline variables in each treat-
ment group was compared with analysis of variance and the
t test (for continuous variables) and chi-square test (for
Figure 1 . Total study group . Numbers in parentheses denote
patients randomized to lbopamine, digoxin or placebo group,
respectively . CHF
-
congestive heart failure .
categoric variables). Differences between the treatment
groups after randomization were analyzed at each scheduled
follow-up visit by comparing the mean change from baseline
with use of analysis of variance and the t test . Use of this
procedure avoided any bias that would have been caused by
including baseline data from patients who were subsequently
withdrawn from the study . For ordinal response data or not
normally distributed variables (such as plasma neurohu-
moral variables) nonparametric methods, such as the
Wilcoxon two-sample rank-sum test were used ; therefore,
these variables are given as median values instead of group
means. Values are mean value ± SD unless indicated
otherwise. All p values reported are for two-tailed tests, and
a two-tailed alpha of <0 .05 was considered statistically
significant.
Results
Of the 180 randomized patients, 19 (11%) were excluded
from analysis before unblinding of the trial code because
they did not fulfill the entry criteria ; the reasons for exclu-
sion are given in Figure 1 . The remaining 161 patients formed
the study group and their baseline characteristics are shown
in Table 1 . There were no significant differences between the
three groups. Of the 161 patients, 128 (80%) completed the
study: 89% of patients receiving digoxin, 72% of patients
receiving ibopamine and 77% of patients receiving placebo
(Fig. 1). Total mortality during the study period was not
1566
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Table L Baseline Characteristics in the Three Imsawnt Groups (161 patients)
different among the ibopamine (n = 1), digoxin (n = 2) and
placebo (n = 3) groups . Five of the six deaths were of
cardiac origin, of which four were sudden (two each in the
digoxin and placebo groups) and one death was due to
progressive pump failure (ibopamine group) . One patient
(placebo group) died of septic shock. With intention to treat
analysis, one additional noncardiac death occurred in a
patient initially randomized to ibopamine .
Premature discontinuation of the study . Of the 161 pa-
tients, 33 did not complete the study and the remaining 128
patients were analyzed for all end points. In the ibopa6ne
group, 6 of the 53 patients withdrew from the trial because of
progressive heart failure, compared with none of the 55
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.
tBOPAM!NE AND DIGOXIN IN CHRONIC HEART MIURE
*Values are mean value ± SD unless otherwise indicated
. tSee text for explanation
. Values are given as median .
patients in the digoxin group (p < 0.05) and 2 of the 53
patients in the placebo group (ibopamine vs . placebo p =
NS) (Fig. 1). The eight patients who discontinued the study
prematurely because of progression of heart failure had a
lower ejection fraction (mean 0.20 ± 0.06), reduced exercise
tolerance (mean 403 ± 88 s) and a higher plasma norepineph-
rine level (median 517 pg/ml) at baseline compared with
patients who completed the trial (p < 0.05) . All these eight
patients were taking furosemide at baseline (mean 60 mg
[four patients receiving 40 mg, four patients receiving
80 ing)) . Furthermore, baseline ambulatory ECG recordings
were available in seven of the eight patients, and six (86%) of
these seven patients had runs of ventricular tachycardia
Ibopamine
(n = 53)
Dig=in
(H = 55)
Placebo
(n = 53)
Age (W) 60±8
61±9 61±8
% Male 85
89 83
Left ventricular ejection fraction 0.29±0 .10 0.28±0 .08 0.30±0 .08
New York Heart Association class (%)
81 80 79
III 19 20 21
Cause of heart A'aildie
Isehemic 85 69 70
Idiopathic 15 31 30
Exercise tolerance (s) 536 ± 206 508 ± 200 499 ± 182
Symptoms of heart failuret
Standardized heart failure score
2 .9±0 .9 3.0±0.9
3.0±1 .0
Visual analog SMIC 6.5±3 .3 7.3±4.0 7.1±3.5
Angina pectoris (%) 15 13 17
Hemodynamic data
Systolic blood pressure (mm 11g) 133 ± 18 131 ± 18 134 ± 18
Diastolic blood pressure (mm Hg) 82±8 81±8 83±9
Heart rate (beats/min) 81 ± 15
78 ± 12 77 ± 15
Presence of S3 and/or S4 gallop 15 16 23
Plasma neurohormones-1
Norepinephrine (pg/mi) 400 438 380
Aldosterone (pg/ml)
93 118 90
Renin (ng/ml per h) 16 25 16
Biochemical measurements
Serum sodium (mmol/liter)
142±3 142±2 1a1±2
Serum potassium (mmol/liter) 4.2±0.3 4.3±0.4
4.2±0.4
Serum creatinine (pmol/liter) 99 :t 23 98 ± 20
98 ± 18
Serum urea (mmol/liter)
6.8±1 .7 7.0±2.0 6.5±1 .7
Arrhythmias on 24-h electrocardiogram
Ventricular premature beats/24 h (no.)t
278 283 268
Ventricular couplets/24 h (noj#
6 2 10
Runs ventricular tachycardial24 h tno .)t 3 3
2
Runs ventricular tachycardia (%)
11 26 32
Runs supraventricular tachycardia (%)
32 37
23
Concomitant drug therapy
Furosemide dose (mg/day)
28 ± 28 25 ± 25
27 ± 26
Triamterene (%) 28
31 21
Antiarrhythmic drugs M
8 11
15
Sublingual nitrates (%)
15
9 it
Anticoagulants (%)
47 33 42
Antiplatelet agents (%) 26
33
17
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(median 71 runs, range 2 to 598). which was a markedly
higher proportion than that in the group as a whole (p 4: (105)
(Table 1). There were no differences between treatment
groups in the number of patients who dropped out for other
reasons (Fig . 1) .
Erects on exercise time. Among the 128 patients who
completed the trial, there were no statistically significant
changes in exercise time after 3 and 6 months (Fig. 2) . After
6 months, an increase of 12 s (95% confidence interval [CI)
-21 to -444 s) in the ibopamine group and of 8 s (95% CI -16
to +33 s) in the digoxin group was observed, compared with
a 129-s decrease in the placebo group (95% CI -6l to +3 s) .
Intention to treat analysis (161 patients) revealed that
digoxin had a significantly different effect on exercise time
than did placebo, as digoxin preserved exercise time over 6
months, compared with a median decrease of 60 s in the
placebo group (p = 0,008) (Fig . 2). The median decrease in
the ibopamine group was 15 s (p = NS vs . placebo) .
On subgroup analysis (128 patients), ibopamine signifi-
cantly increased exercise time compared with placebo in
Patients with relatively preserved left ventricular function, in
particular in those with an ejection fraction of >0.30 (Fig . 2),
New York Heart Association functional class 11, low plasma
aldosterone (a IOMO pg1ml), low plasma renin (<_20 ngiml per
h) or no ventricular tachycardia on baseline ambulatory
ECG monitoring (Table 2) . Digoxin did not seem to show
such a pattern, although it tended to have a more favorable
effect in subgroups with more impaired left ventricular
6300-00
Figure 2. Change in exercise time
(ins) between randomization and
3 and 6 months of treatment . *p <
0.05. Values for patients who
completed the study are mean
changes ; intention to treat (worst
case) analysis was performed with
data that show an abnormal distri-
bution and these values are me-
dian changes. EF = left ventricu-
lar ejection fraction .
r ®i
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function (Table 2) . However, if the intention to treatt princi-
ple was also applied to the subgroup analysis, the difference
between digoxin and placebo became significant, favoring
digoxin (for example, for patients with a left ventricular
ejection fraction !:-:0,30, p = 0.001 vs. placebo) . For ibopa-
mine, the results of the intention to treat analysis were
generally comparable to those of the analysis of only those
who completed the trial . In subjects who were not using
diuretic agents, both ibopamine and digoxin were signifi-
cantly more effective than placebo as monotherapy .
Signs and symptoms of heart failure. At study entry, all
patients were in New York Heart Association functional
class 11 or III . Although an overall slight improvement in
functional class was observed after 6 months, there were no
significant changes between the three treatment groups .
During the study, no significant differences were seen in the
dose of furosemide. Symptoms during daily life, as assessed
by a standardized heart failure score and a visual analog
scale, were equal in the three groups at baseline (Table 1) .
After 6 months, patients in the ibopamine and digoxin groups
had an improved heart failure score, but only the difference
between the ibopamine and placebo groups was significant
(p < 0.05) (Fig . 3) . With respect to the visual analog scale,
only ibopamine produced a statistically significant reduction
in symptoms during daily life (Fig . 3) .
Biochemical measurements. In the three groups, mean
values of plasma sodium, potassium, creatinine, urea, liver
function tests, glucose and hematologic measurements were
JACC Vol
. 22, No. 6
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Table 2 . Changes in Exercise Time (in seconds) After 6 Months, Related to the Various
1 month
Itiopomine 3 months
0 month*
1 month
Di9oxin 3 moms
0 months
1 month
Plecobo 3 months
a moms
'Groups are divided using rounded off values, closest to the mean/median ; numbers of patients in particular subgroups are shown in parentheses . thlot
available in all patients . tRange 20 to 80 mg. LV = left ventricular; NYHA = New York Heart Association .
not significantly different at baseline and did not change
during 6 on mths of follow-up . Plasma concentratiors of free
epinine were 681 ± 700 pgiml in the ibopamine group, 0 .3 ±
1 .6 pglml in the digoxin group and 0 .1 t 0.5 pg/ml in the
placebo group . Plasma digoxin concentration was 0 .94 ±
0.49 ng/ml in the digoxin group and was not detectable in the
other two groups .
At baseline, neurohumoral measurements were not dif-
ferent among the three groups (Table 1) . During 6 months of
follow-up, plasma norepinephrine increased in the placebo
group (+62 pg/ml, p = 0.018) but decreased in the digoxin
group (-106 pg/ml, p = 0 .004; digoxin vs . placebo, p <
0.001) (Fig . 4) . In the ibopamine group, norepinephrine did
not change significantly during follow-up (-13 pg/ml), but it
was significantly (p < 0.05) lower than the value in the
Heart Failure Score
-4
-1
	
-0,5
0 0.6
mean chanoe a 95% C,
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saline Variables (128 patients)*
placebo group . Baseline norepinephrine and the subsequent
decrease after 3 and 6 months were strongly correlated in
both the ibopamine and digoxin groups but not in the placebo
group (Fig . 5). Aldosterone was not significantly affected
during the study, but renin levels after 6 months were
significantly lower (p < 0 .05) in the ibopamine and digoxin
groups than in the placebo group (Fig . 4) .
Electrocardiographic findings. Of the 161 randomized pa-
tients, 159 (99%) had sinus rhythm and 2 patients had atria)
Figure 3. Symptoms of heart failure and effect of treatment . Left
panel, Standardized heart failure score . Right panel, Visual analog
scale. See Methods section for further explanation . Values are mean
value ± 95% confidence interval (Q . *p < 0 .05 between active
treatment and placebo .
Visual Analog Scale
I month
niapamine 3 months
0 months
1 month
Digoxin 3 months
8 momho
t math
plwcbo 3 months
0 months
-4
I	
0
1,4
3
MUM Chg"a a 05% C1
lboparnine p Vahx
Digcxin p Value Placebo
p Value
(ibopamine vs . digoxin)
(digoxin vs . placebo)
(ibopamine vs . placebo)
LV ejection fraction
>0
.30 (n = 65) +45 (n = 21) 0 .036
-9 (n = 19) NS -25 (n = 25)
0 .018
-sO .30 (n = 63) -29 (n = 17) NS +19 in = 30) NS -35 (n = 16)
NS
NYHA functional 11 (n 104) +23 (n = 33) NS -2 (n = 39) NS -33 (n = 32)
0 .026
class III (n 24) -60(n=5) NS
+49 (a = 10) NS -13 (n = 9)
NS
Exercise time (s) Z-050 (n = 56) A-3 (n = 19) NS -7 (n = 21) NS
-30 (n = 16) NS
5550 (a = 72) +15 (n = 19) NS +20 (n = 28) NS --28 (n = 25) NS
Plasma norepinephrine 5400 (it = 62) +41 (a = 18) NS -4 (n = 18)
NS -- 45 (n = 26) NS
(pg/ml)t >400 (n = 58) -24 (n = 18) NS +21 (n = 28) NS
-5 (n = 12) NS
Plasma aldosterone 5 1 00 pg(ml (n = 57) +48 In = 18) NS +12 (a = 19) NS -42 (n = 20)
0 .012
(pg/mbf
>100 pg/ail (n = 56) -26 (n 17) NS +20 (n = 23)
NS -22 (it = 16) NS
Plasma reniki (ng/ml X21) (a 58) M (n 20) NS +38 (n = 16) 0 .011 --
57 (n ± 22) 0.020
per Wt >>201n 52) + 19 (n 14) NS +3 (n = 25) NS +1 (n = 13) NS
ventricular Absent (n = 87)
+40 In 22)
NS
+20 (n 36)
NS -27 (n = 29) 0.025
lachycardia
Present (a
T
41)
-27 In 16) NS +2 (A 13) NS -35 (n = 12)
NS
Furosemide use No (n 56) 48 (a 19) NS
t-
17 in - 21) 0 .010 -62 (n = 16) < 0 .0001
Yes in 72)f 24 (11
19)
NS 2 (o - 28) NS -8 (n = 25) NS
a x
"I'M
a "WIN
L
-I00 =100 -a0
	
0 ee I00 140
11116" 0P 1N
0
10100810
a 40111110.
Ir M
01~BM a ""IPA
0 lW100
I tO
• a M"INS
0 Min100
-80
I "WIN
100000100 a Months
a Menthol
r
M" M
045 00 a WIN
0 M"100
b
r
IMAM
• a MOMM
0 004100
AMdeeter
-i0 0 IQ
000Q01100000. (o flO
Benin
u \+S\\\\a\a
qN
\\N\C>H+~+++++++\\A
0 a
owl
r 1
4. Changes in plasma norepinephrine, aldosterone and renin
during the 6-month study period. Values are median change from
line . 0 p < 0.05 and *""p < 0.001 between active treatment and
placebo,
fibrillation (1 receiving ibopamine, 1 receiving placebo) .
During the 6-month study period, five patients with sinus
rhythm developed either atrial fibrillation (three patients) or
flutter (two patients) (two receiving digoxin, three receiving
placebo) .
Ambulatory 24-h ECG recordings at baseline and after 3
months were available in 124 of the 161 patients . At baseline,
the number of ventricular and supraventricular arrhythmias
was similar in the three groups (Table 1), and there were no
significant changes in the three treatment groups after 3
months
. According to the criteria of Morganroth and Horow-
itz (14), 28 (23%) of the 124 patients had an increase in
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Figure S. Scatterplots of correlation between baseline plasma nor-
epinephrine concentrations and subsequent changes after 6 months
of treatment for the ibopamine, digoxin and placebo groups,
arrhythmias, but there were no statistically significant differ-
ences among the ibopamine group (14%, 5 of 37 patients),
the digoxin group (26% . 11 of 43) and the placebo group
(27%, 12 of 44) .
Side effects . Patients in whom adverse effects led to
premature discontinuation of the trial are shown in Figure 1 .
The remaining 128 patients who completed the study re-
ported a total number of 92 side effects (Table 3), of which
gastrointestinal complaints were the most frequent . Patients
receiving digoxin had significantly more side effects ; partic-
ularly nausea and vomiting (p < 0 .05 vs. placebo). However,
digoxin concentrations were not higher in these patients than
in patients without complaints . Ibopamine was not associ-
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Table 3. Incidence of Side Effects During 6 Months of Follow-Up
(128 patients)
"A patient may have more than one side e ffect . tp < 0 .05 .
ated with a greater incidence of side effects than that
associated with placebo .
Discussion
This study shows that even in patients with a mild degree
of chronic heart failure, a slight but significant deterioration
is observed over 6 months . Although both ibopamine and
digoxin inhibit neurohumoral activation in this patient group,
their clinical effects are different and appear to be related to
the degree of left ventricular dysfunction .
In a previous controlled study with ibopamine (15), the
drug was found to be as effective as digoxin in a patient
group similar to ours. In subjects with more advanced heart
failure and background therapy of digoxin and diuretic
agents, ibopamine was reported to be as effective as capto-
pril (16), whereas a recently published placebo-controlled
study (17) in patients already treated with angiotensin-
converting enzyme inhibitors showed that no tolerance
developed after long-term treatment . In the present study,
ibopamine re&ced signs and symptoms of heart failure and
was well tolerated, but a favorable effect on exercise time
was observed only in patients with relatively preserved left
ventricular function . In more advanced stages of the disease,
however, combined treatment with diuretic agents and
digoxin or angiotensin-converting enzyme inhibitors may be
required to prevent deterioration of heart failure because 6 of
53 patients receiving ibopamine dropped out of the present
study because of progression of heart failure compared with
none of the 55 patients receiving digoxin . Because of the
relatively small number of patients, it is impossible to
examine the safety of ibopamine in this respect or to
determine from the present data whether ibopamine was
unable to prevent deterioration or actually contributed to the
adverse outcome . By study design, patients who were al-
ready taking 80 mg of furosemide at baseline could be
included, but a requirement for an increased dose during the
study implied premature discontinuation of the study . In-
deed, the patients who dropped out because of progression
VAN VELDHUISEN ET AL
.
	
1571
IBOPAMINE AND DIGOXIN IN CHRONIC HEART FAILURE
of heart failure (in both the ibopamfne and placebo groups)
had more severe heart failure and a higher dose of diuretic
drug at entry than did those who completed the trial .
The benefit of digoxin in patients with sinus rhythm and
chronic heart failure has often been questioned, and the
pooled data from the three large scale, placebo-controlled
studies with digoxin (18-20) suggest that its value is mainly
restricted to patients with moderate to severe heart failure .
In our study, digoxin caused an increase in exercise time on
intention to treat analysis, and subgroup analysis indicated
that this beneficial effect was mainly found in patients with
more advanced heart failure . Also, no patient receiving
digoxin withdrew from the study because of progression of
heart failure during 6 months of follow-up. However, pa-
tients receiving digoxin had significantly more nausea and
vomiting (13 of 55) than did patients receiving placebo (2 of
53), although this led to discontinuation of the study in only
2 patients . Digoxin significantly reduced plasma norepineph-
rine and plasma renin levels . The latter influence, albeit
small, may be a direct renal effect of digoxin (21), but it may
also be secondary to a reduction in sympathetic activity (22) .
We believe that our study is the first large scale trial to report
this neurohumoral-inhibiting effect of long-term digoxin
treatment .
Ibopamine also lowered plasma norepinephrine and renin
levels after 6 months compared with levels achieved with
placebo. Although this effect may be secondary to this
drug's hemodynamic influence, direct receptor (dopamine 2
and possibly alpha
2
-dopamine) activation by ibopamine, or
rather epinine, may also lower plasma norepinephrine con-
centrations (4-6) . This reduction in plasma norepinephrine
levels increases as baseline levels are more elevated, as was
shown in the present study (Fig . 5), but also in previous
reports (23) in which ibopamine progressively blunted the
increase in plasma norepinephrine levels during exercise .
Although a decrease in plasma aldosterone after administra-
tion of ibopamine has been reported (24), this was not found
in the present study . Indeed, ibopamine treatment probably
leads to a reduction in aldosterone only in the presence of
sodium depletion (when aldosterone secretion is stimulated
by angiotensin II) by direct dopamine 2-receptor stimulation
(24) .
Four of the five cardiac deaths during the study were
sudden, but there was no relation between baseline arrhyth-
mias or development of proarrhythmia and sudden death .
Neither ibopamine nor digoxin caused significant proar-
rhythmic effects compared with placebo. Analysis of pa-
tients who prematurely discontinued the study because of
progression of heart failure revealed that they had a mark-
edly higher incidence of ventricular tachycardia and number
of runs/24 h on the baseline ambulatory ECG recording than
did those who completed the study . This finding confirms
previous suggestions (25) that ventricular arrhythmias are a
marker of the severity of the disease or of clinical instability
rather than a predictor of sudden death .
There is increasing evidence 'fat the progression of heart
Side Effect'
Ibopamine
(n = 38)
Digoxin
(n = 49)
Placebo
(n = 41)
Cardiovascular
Palpitation I 4 2
Chest pain 2 1 I
Dizziness 2 4 4
Gastrointestinal
Nausea/vomiting 3
Other 7 7 3
Headaches/sleeplessness 3 8 6
Skin dryness/rash 3 1 4
Other 5 5 4
Total 26 41t 25
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failure is related to chronic neurohumoral activation (1,2) .
Drugs that delay, inhibit or blunt this activation, the so-
called neurohumoral antagonists (26), may improve the
prognosis once the disease is present (27) or even prevent
the incidence of heart failure in patients with asymptomatic
left ventricular dysfunction (28). Drugs like phosphodiester-
ase inhibitors and direct-acting vasodilators exert potent
hemodynamic effects but also further increase neurohumoral
activation in heart failure, and long-term studies (26) have
found either an adverse or no effect on prognosis with these
drugs. Therefore, it appears that neurohumoral inhibition
may be more important than an (initial) beneficial hemody-
namic effect, was recently demonstrated in the V-HeFT 11
study (27). In that study, the angiotensin-converting enzyme
inhibitor enalapril, a drug that inhibits neurohumoral activa-
tion, favorably affected prognosis compared with the com-
bination of isosorbide dinitrate-hydralazine, drugs that im-
prove hemodynamics but increase neurohumoral activation .
The beneficial long-term effects of beta-adrenergic blocking
agents, which may have an unfavorable acute hemodynamic
effect in patients with heart failure, support this hypothesis
(29).
Angiotensin-converting enzyme inhibitors have become
the most important drugs and are currently a cornerstone in
the treatment of heart failure (30) . Ibopamine and digoxin
have relatively mild hemodynamic effects, but they inhibit
neurohumoral activation in this syndrome and both drugs
can thus be classified as neurohumoral antagonists . In light
of these findings, it would be interesting to know how they
affect survival in heart failure-either alone, when compared
with angiotensin-converting enzyme inhibitors, or as an
adjunct to these drugs. The apparent safety of both digoxin
and ibopamine allows such a trial, which would further
broaden our view on the relation between hemodynamic
effects and neurohumoral modulation in the treatment of
hew failure,
Appendix
The Dutch Ibopamine Multicenter Trial Study
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Center, Department of CardiologylThoraxcenter, and Wick H. van Gilst,
PhD, Institute of PharmacologylClinical Pharmacology . University Hospital,
Groningen.
Participating Centers and Principal Investigators . Ignatius Ziekenhuis,
Breda, Peter H . J . M . Dunselman, MD ; St. Geertruiden Ziekenhuis, Deven-
ter, Dirk J . A. Lok, MD; Groot Ziekengasthuis's Hertogenbosch, Henk J . M .
Dohmen, MD; Refgja Ziekenhuis, StadskanaallDejf zichr Ziekenhuis, Dejfz-
tjl, Dirk J . van Veldhuisen, MD
; Medisrh Spectrum Twente Enschede, J
.
Cees
Poortermans, MD
; Reinier de Grad Ziekenhuis Delft,
Adrie J. A. M
.
Withagen, MD
;
St
. Elisabeth Ziekenhuis, Tilburg, J
. Hans Pasteuning, MD ;
St. Lucas Ziekenhuis, Amsterdam, Willem G. de Voogi, MD; St . Joseph
Ziekenhuis, Eindhoven, Andries H. Bosma, MD; Maria Ziekenhuis, Tilburg,
Henri A. M. van Kesteren, MD; Zuiderzeeziekenhuis Lelystad, Peter de
Webrd, MD ; IJsselland Ziekenhuis, Rotterdam, Brian J . van den Berg, MD ;
Academisch Medisch Centrum . Amsterdam, Donald R . Dilrcn, MD; Zieken-
huis NU Smellinge, Drachien, Jan Brouwer, MD ; Sophia Ziekenhuis Lwolle,
Rob Enthovcn . MD; Catharina Ziekenhuis, Eindhoven, Mandouh I . H . El
Gamal, MD ; Rooms Katholiek Ziekenhuis, Groning en, Enno Laverman, MD
.
References
I . Weber KT, Anversa P . Armstrong PW, et al. Remodeling and reparation
of the cardiovascular system. J Am Coll Cartliol 1992 ;20 :3-16.
2 . Packer M . The ,oeurohormonal hypothesis : a theory to explain the
mechanism of disease progression in heart failure, I Am Coll Cardiol
1992 .0;248-54,
3 . Henwood JM, Todd PA . Ibopamine : a preliminary review of its pharma-
codynamic wnd phanaacokinetic properties and therapeutic efficacy .
Drugs I ;36 :11-31 .
4 . Brodde GE . /3s- and /. . •Adrenoceptors in the human heart : properties,
function, and alterations in chronic heart failure . Pharmacol Rev 1991 ;43 :
203-42 .
5, ltoh H. Clinical pharmacology of ibopamine
. Am J pled 1991 ;90 Suppl
SB;36S-42S .
6, Rousseau MF, Raigoso J, Van Eyll C, et al . Effects of intravenous epinine
administration on left ventricular systolic performance, coronary hemo-
dynamics, and circulating catecholamines in patients with heart failure .
I Cardiovasc Pharmacol 1992 ;19:155-62 .
7 . Rifer SI, Rossen JD, Douglas FL
. Goldberg LI, Karrison T . Effects of
long-term therapy with oral ibopamine on resting hemodynamics and
exercise capacity in patients with heart failure : relationship to the
generation of N-methyldopamine and plasma norepinephrine levels . Cir-
culation 1986;73 :740-8.
8
. Van Veldhuisen DJ, Cr jns HJ, Girbes ARJ, Tobe TJM, Wiesfeld ACP,
Lie KI
. Electrophysiologic profile of ibopamine in patients with conges-
tive heart failure and ventricular tachycardia and relation to its effects on
hemodynamics and plasma catecholamines . Am I Cardiol 1991 ;68:1194-
202.
9. Ferguson DW, Berg WJ, Sanders IS
. Roach PJ, Kempf JS, Kienzle MG.
Sympathoinhibitory responses to digitalis glycosides in heart failure
patients: direct evidence from sympathetic neural recordings . Circulation
1989 ;80:65-77 .
10 . Jaeschke R, Oxman AD, Guyatt GH
. To what extent do congestive heart
failure patients benefit from digoxin therapy? A systematic overview and
meta-analysis . Am J Med 1990 ; :279-86.
It . Gheorghiade M, Ferguson D. Digoxin: a neurohumoral modulator in heart
failure? Circulation 1991 ;84:2181-6 .
12
. Boomsma F, Alberts G, Van Der Hoorn FAJ, Man in 't Veld AJ,
Schalekamp MADH
. Simultaneous determination of free catecholamines
and epinine and estimation of total epinine and dopamine in plasma and
urine by high-performance liquid chromatography with fluorimetric de-
tection . J Chromatogr 1992 ;574:109-17 .
13
. Derkx FHM, Tan-Tjong IL, Wenting GJ, Boomsma F, Man in 't Veld AJ,
Schalekamp MADH
. Asynchronous change in prorenin and renin secre-
tion after captopril in patients with renal artery stenosis
. Hypertension
1983;5 :244-56
.
14
. Morganroth J, Horowitz LN . Flecainide
: its proarrhythmic effect and
expected changes on the surface electrocardiogram
. Am J Cardiol 1984 ;
53 :89B-94B .
15
. Cavalli A, Riva E, Schleman M, Abbondati G, Fuccella LM, Smith Kline
and French Ibopamine Group. Ibopamine as a substitute for digitalis in
patients on chronic digoxin therapy
. Int J Cardiol 1989 ;22:381-7.
JACC Vol . 22, No . 6
November 15, 1993 :1564-73
16, Barabino A, Galbariggi G, Pizzorni C, Lotti G . Cnmparative effects of
long-term therapy with captopril and ibopamine in chronic congestive
heart failure in old patients . Cardiology 1991 -,78:243-56 .
17 . Dei Cas L, Metra M, Visioli 0. Effects of acute and chronic ibopamine
administration on resting and exercise hemodynamics, plasma catechola-
mines and functional capacity of patients with chronic congestive heart
failure. Am J Cardiot 1992 ;70:629-34,
18 . The German and Austrian Xamoterol Study Group . Double-blind placebo
controlled comparison of digoxin and xamoterol in chronic heart failure .
Lancet 1988 ;1 :489-93.
19 . The Captopril-Digoxin Multicenter Research Group . Comparative effects
of therapy with captopril and digoxin in patients with mild to moderate
heart failure . JAMA 1988
;259 :539-44 .
20. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for
the Milrinone Multicenter Trial Group . A comparison of oral milrinone,
digoxin, and tneir combination in the treatment of patients with chronic
heart failure
. N Eng] J Med 1989 ;320 :677-83 .
21
. Lloyd MA, Sandberg SM, Edwards BS . Role of renal Na', K'-ATP-ase
in the regulation of sodium excretion under normal conditions and in
acute congestive heart failure . Circulation Wo2 ;85 :1912-7 .
22. Thames MD. Acethylstrophanthidin-induceo reflex inhibition of canine
renal sympathetic nerve activity mediated by cardiac receptors with vupd
afferems . Circ Res 1979
;44:8-15 .
B. Cubes ARL Van VeldhWwn 0J, Grevink RA Smit At 110som WD
.
VAN VELDHWSEN, ET AL .
	
1573
tBOPAMINE AND DIGOXIN IN CHRONIC HEART FAILURE
Effects of ibopamine on exercise-induced increase in norepinephrine in
normal men. J Cardiovasc Pharmacol 1992 ;19:371-4 .
24 . Missale C, Metra M
. Sigala S, Memo M, Dei Cas L, Spano PF . Inhibition
of aldosterone secretion by doparnine, ib3parnine, and dihydroergotoxine
in patients with congestive heart failure . J Cardiovasc Pharmacol 1989
;14
Suppi B :S72-0.
25 . Packer M . Lack of correlation between ventricular arrhythmias and
sudden death in patients with chronic heart failure
. Circulation 1992;85
Suppl 1 :1-50-6 .
26 . Packer M
. Vasodilator and inotropic drugs for the treatment of chronic
heart failure : distinguishing hype from hope
. J Am Coll Cardiol 1988 ;12 :
1299-317
.
27 . Colin JN, Johnson G, Ziesche S, et al . A comparison of enalapril with
hydralazine-isosorbide dinitrate in the treatment of chronic congestive
heart failure . N Engi J Med 1991,325 :303-10.
28, The SOLVD Investigators . Effect of enalapril on mortality and the
development of heart failure in a5yinplomalic patients with reduced left
ventricular ejection fractions. N Engl J Plied 1992 ;327:685-91 .
29. Waagstein F, Caidahl K, Wallentin I, Bergh 01, Kjalm-arson
A .
Lang-
term f3-blockade in dilated cardiomyopathy
: effects of short-term meto-
proioi ifemmuhn folluwed by withdrawal and readministration of melo-
pnAoL Circulation 1989 ;80:551-63 .
30. Braunwald E . ACE inhibitors : a cornerstone of the treatment of heart
failure . N MW J MW 1991:325 :351-3 .
